Novel quinoline derivatives and their applications
AssigneeShenyang Pharmaceutical University
InventorsPing Gong, Yanfang Zhao, Yajing Liu, Xin Zhai
Life of this patent
Estimating the term…
Abstract
The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.
Claims17
Compounds of formula I, and their pharmaceutically acceptable salts, hydrates, or prodrugs,
- wherein,
- X is O, S, NH or NCH3;
- Y can be 1-4 substituents optionally selected from halogen, trihalomethyl, methyl, cyano and nitro groups;
- M is
- is O or S;
- n is an integer between 1 and 6;
- R1 and R2, which are same or different, are independently selected from hydrogen, (C1-C10) alkyl, (C3-C7) cycloalkyl, (C2-C10) alkenyl and (C2-C10) alkynyl, wherein R1 and R2 are optionally substituted with 1-3 same or different R3;
- or
- R1 and R2 together with the nitrogen atom to which they are attached form 5- to 10-membered heterocyclic radical or 5- to 10-membered heteroaryl radical, wherein, besides the nitrogen atom to which R1 and R2 are attached, the said heterocyclic and heteroaryl radicals may contain 1 to 4 heteroatoms selected from N, O and S, and wherein the said heterocyclic radical may optionally contain 1 to 2 carbon-carbon double bonds or triple bonds, and wherein said heterocyclic and heteroaryl radicals can be optionally substituted with 1 to 3 same or different R3;
- R3 and R4 are independently hydrogen or (C1-C6) alkyl;
- Ar is (C6-C10) aryl or 5- to 10-membered heteroaryl radical, wherein said heteroaryl radical may contain 1 to 3 heteroatoms selected from N, O and S and may be optionally substituted with 1 to 3 same or different R5;
- and
- R5 is hydroxyl, halogen, nitro, amino, cyano, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxyl, (C1-C6) alkyl or (C1-C6) alkoxyl which is optionally substituted with hydroxyl, amino or halogen, amino group substituted with 1 or 2 (C1-C6) alkyl groups, (C1-C6) alkylcarbonylamino, carboxyl group which can be free acids, salts, amidated or form ester group, (C1-C6) alkylsulfinyl, (C1-C6) alkylsulfonyl, (C1-C6) alkylacyl, carbamoyl, carbamoyl substituted with for 2 (C1-C6) alkyl, (C1-C3) alkylenedioxo, or allyl.
-15. (canceled)
A method for treating a disease characterized by aberrant c-Met kinase activity comprising administering, to a patient in need thereof, a therapeutically effective amount of a compound, a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.
Dependencies are inferred from the claim text.